First Eagle Investment Management LLC cut its stake in shares of AxoGen, Inc. (NASDAQ:AXGN – Free Report) by 53.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 318,702 shares of the medical equipment provider’s stock after selling 363,452 shares during the quarter. First Eagle Investment Management LLC’s holdings in AxoGen were worth $13,360,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in AXGN. BlackRock Inc. acquired a new position in shares of AxoGen in the second quarter valued at approximately $204,123,000. Artemis Investment Management LLP lifted its holdings in AxoGen by 27.5% during the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after purchasing an additional 384,200 shares during the last quarter. Wellington Management Group LLP lifted its holdings in AxoGen by 44.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock worth $64,280,000 after purchasing an additional 427,089 shares during the last quarter. Bamco Inc. NY acquired a new stake in AxoGen during the 2nd quarter worth approximately $34,190,000. Finally, TimesSquare Capital Management LLC bought a new stake in AxoGen in the 2nd quarter valued at $31,863,000. Institutional investors own 80.29% of the company’s stock.
Analysts Set New Price Targets
Several analysts recently issued reports on AXGN shares. HC Wainwright boosted their price target on AxoGen from $53.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Raymond James Financial reiterated an “outperform” rating and set a $57.00 price objective on shares of AxoGen in a research report on Thursday, October 29th. Citigroup reissued a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of AxoGen in a research report on Wednesday, October 28th. Finally, Lake Street Capital restated a “buy” rating and issued a $58.00 price target on shares of AxoGen in a research note on Thursday, October 29th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.92.
Get Our Latest Stock Analysis on AXGN
Insider Buying and Selling
In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the transaction, the director directly owned 10,650 shares of the company’s stock, valued at $529,305. The trade was a 24.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by company insiders.
AxoGen Stock Up 2.9%
Shares of AXGN opened at $56.95 on Thursday. AxoGen, Inc. has a 12 month low of $23.61 and a 12 month high of $59.72. The firm’s 50 day moving average is $43.78 and its 200-day moving average is $40.76. The stock has a market capitalization of $3.40 billion, a PE ratio of -87.62 and a beta of 1.21. The company has a current ratio of 12.02, a quick ratio of 10.67 and a debt-to-equity ratio of 0.04.
AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. Equities research analysts forecast that AxoGen, Inc. will post -0.36 EPS for the current year.
AxoGen Profile
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Featured Stories
- Five stocks we like better than AxoGen
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN – Free Report).
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
